A Joint Clinical Research Center in Thailand: Role in HIV vaccine development

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 34, Issue 1, 2003, Pages 126-135

  Morgan, Patricia A ^a,b   Chinaworapong, Suchada ^a   Excler, Jean Louis ^a,b   Wongkamheng, Siriluck ^a   Triampon, Attapon ^a   Buapunth, Puangmalee ^a   Nitayaphan, Sorachai ^a   Michael, Rodney A ^a   Singharaj, Pricha ^a   Brown, Arthur E ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARMY; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; GOVERNMENT; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THAILAND; UNITED STATES; UNIVERSITY; VOLUNTEER;

EID: 0043068260     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. AFRIMS website: www.afrims.org [Accessed 17 May 2001].
2. Brown AE, Nitayaphan S, Sukwit, S, et al. DTH responsiveness of HIV-infected Thai adults. J Med Assoc Thai 2000; 83: 633-9.
3. Buapunth P, Chinaworapong S, Triampon A, et al. Experience of mucosal specimen collection from HIV sero-positive and sero-negative volunteers in Thailand. Melbourne: Sixth International Congress on AIDS in Asia and the Pacific, 5-10 October 2001 [abstract 1473].
4. Chinaworapong S, Buapunth P, Morgan PA, et al. Motivation for interest and reasons for exclusion in a Phase I/II HIV-1 vaccine trial in Thailand. Vancouver: Eleventh International Conference on AIDS, 7-12 July 1996 [abstract We.C.211].
5. Chinaworapong S, Nitayaphan S, Morgan PA, et al. Motivation and recruitment for Phase I/II HIV-1 prime boost vaccine. Melbourne: Sixth International Congress on AIDS in Asia and the Pacific, 5-10 October 2001 [abstract 849].
6. Chuenchitra T, Rungruenghanakit K, de Souza MS, et al. Anti-gp120 humoral responses of subjects enrolled in a phase I HIV recombinant protein (gp120/SF2) vaccine trial in Thailand. Manila: Fourth International Congress on AIDS in Asia and the Pacific. 25-29 October 1997 [abstract B (P) 009].
7. Chuenchitra T, Wasi C, Louisirirotchanakul S, et al. Immune Correlates of HIV-1 Disease Progression in Subtype E-Infected Thais. Philadelphia: AIDS Vaccine 2001, 5-8 Sep 2001 [abstract 141].
8. Commission on Health Research for Development. Health research: essential link to equity in development. New York: Oxford University Press, 1990.
9. Costello A, Zumla A, Moving to research partnerships in developing countries. Br Med J 2000; 321: 827-9.
10. de Souza MS, Chuenchitra T, Ratto KS, et al. Lymphoproliferative responses of patients enrolled in a phase I HIV recombinant gp120 SF2 trial in central Thailand. Manila: Fourth International Congress on AIDS in Asia and the Pacific. 25-29 October 1997 [abstract B (P) 131].
11. de Souza, MS, Karnasuta, C, Brown, AE, et al. A comparative study of the impact of HIV infection on natural killer cell number and function in Thais and North Americans. AIDS Res and Hum Retroviruses 2000, 11:1061.
12. de Souza M, Karnasuta C, Cox J, et al. Cytotoxic T-Lymphocyte Responses in Volunteers Enrolled in a Phase I/II HIV-1 Prime-Boost Trial in Thailand. Philadelphia: AIDS Vaccine 2001, 5-8 Sep 2001a [abstract 322].
13. de Souza MS, Trichavaroj R, Sriplienchan S, et al. Detection and quantification of HIV-1 RNA in nasopharyngeal washes from HIV-1-infected subjects. AIDS Res Hum Retroviruses 2001b; 17: 229-32.
14. Global Forum for Health Research. The 10/90 report on health research 2000. Geneva: Global Forum for Health Research, 2000.
15. Harris E, Tanner M. Health technology transfer. Br Med J 2000; 321: 817-20.
16. Heyward WL, Osmanov S, Esparza, J. Establishment of WHO-sponsored field sites for HIV vaccine evaluation in developing countries, Antibiot Chemother 1996, 48: 139-44.
17. Jenkins RA, Temoshok LR, Virochsiri K, et al. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol. 1995, 9: 36-42.
18. Jenkins RA, Thapinta D, Celentano D, et al. Behavioral characteristics of Thai vaccine trial volunteers. Vancouver: Eleventh International Conference on AIDS, 7-12 July 1996 [abstract Mo.C.1588].
19. Jenkins RA, Chinaworapong S, Morgan PA, et al. Motivation, recruitment, and screening of volunteers for a Phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovir 1998; 18:171-7.
20. Loomis-Price L, Lyons A, Polonis V, et al. Phase I vaccine trial of rgp 120 subtype E and rgp 120 subtype B in Thailand: immunologic results. Melbourne: Sixth International Congress on AIDS in Asia and the Pacific, 5-10 October 9001 [abstract 1344].
21. Lynch JA, de Souza MS, Robb MD, et al. Cross-clade cytotoxic T cell response to HIV-1 proteins among HLA disparate North Americans and Thais. J Infect Dis 1998, 178:1040-6.
22. McCutchan FE, Viputtigul K, de Souza MS, et al. Diversity of envelope glycoprotein from Human Immunodeficiency Virus type 1 of recent seroconverters in Thailand. AIDS Res Hum Retrovir 2000; 16: 801-5.
23. McNeil JG. A Decade of HIV Vaccine Development in Thailand. Philadelphia; AIDS Vaccine 2001. 5-8 Sep 2001 [abstract 323]
24. st ed. Thailand: The Ministry of Public Health of Thailand, 1993.
25. th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS (NCVDG), 11-15 February 1996 [abstract 108].
26. Morgan P. An HIV Vaccine Clinical Trials Center in Thailand. Melbourne: Sixth International Congress on AIDS in Asia and the Pacific, 2001 [abstract 0811].
27. National Intelligence Council. The global infectious disease threat and its implications for the United States. National Intelligence Estimate 2000. www.cia.gov/cia/publications/nie/report/nie99-117d.html. [Accessed 17 May 2001].
28. Nitayaphan S, Khumboonruang C, Chiu J, et al. Post-immunization reactogenicity and toxicity of Biocine HIV SF2 gp120/MF59 vaccine in seronegative Thai volunteers. Bethesda; Eighth Annual Meeting of the NCVDG, 11-15 February 1996 [abstract P#66].
29. Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000; 18:1448-55.
30. Nitayaphan S, Pitisuttithum P, Singharaj P, et al. Safety of live recombinant ALVAC-HIV (vCP1521) priming with AIDSVAX B/E boosting in Thai HIV-1-negative participants: preliminary results. Philadelphia: AIDS Vaccine 2001. 5-8 Sep 2001 [abstract 237].
31. Pitisuttithum P, Tongcharoen P, Khamboonruang C, et al. Phase II trial of HIV-1 subtype E and B gp120 vaccines in seronegative Thai adults. Durban: South Africa, Thirteenth International AIDS Conference. 9-14 July 2000 [abstract WePe C4470].
32. Polonis V, Kim J, Nitayaphan S, et al. HIV neutralizing antibodies in seronegative volunteers in a phase I/II Prime-Boost Vaccine Trial in Thailand. Philadelphia: AIDS Vaccine 2001, 5-8 Sep 2001 [abstract 316].
33. Thapinta D, Jenkins RA, Celantano D, et al. Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers. J Acquir Immune Defic Syndr Hum Retrovir 1999; 20: 308-14.
34. Tovanabutra S, Polonis V, de Souza MS et al. First CRF01_AE/B recombinant of HIV-1 is found in Thailand. AIDS 2001; 25:1063-5.
35. Triampon A. Experience from the successful conduct of a Phase I/II trial of a gp120 HIV vaccine. Melbourne: Sixth International Congress on AIDS in Asia and the Pacific, 5-10 October 2001 [abstract 1205].
36. Trichavaroj R, de Souza MS, Buapunth P, et al. HIV viral load in Thai men and women with subtype E infections. J AIDS 2001; 26:345-7.